WO2002044737A3 - Compositions pour applications diagnostiques et therapeutiques et methodes associees au recepteur couple aux proteines g (gpcr) le recepteur anaphylatoxine c3a - Google Patents

Compositions pour applications diagnostiques et therapeutiques et methodes associees au recepteur couple aux proteines g (gpcr) le recepteur anaphylatoxine c3a Download PDF

Info

Publication number
WO2002044737A3
WO2002044737A3 PCT/US2001/045220 US0145220W WO0244737A3 WO 2002044737 A3 WO2002044737 A3 WO 2002044737A3 US 0145220 W US0145220 W US 0145220W WO 0244737 A3 WO0244737 A3 WO 0244737A3
Authority
WO
WIPO (PCT)
Prior art keywords
anaphylatoxin
receptor
diagnostic
therapeutic compositions
methods related
Prior art date
Application number
PCT/US2001/045220
Other languages
English (en)
Other versions
WO2002044737A2 (fr
Inventor
Joseph P Brown
Glenna C Burmer
Christine L Roush
Douglas A Morningstar
Original Assignee
Lifespan Biosciences Inc
Joseph P Brown
Glenna C Burmer
Christine L Roush
Douglas A Morningstar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lifespan Biosciences Inc, Joseph P Brown, Glenna C Burmer, Christine L Roush, Douglas A Morningstar filed Critical Lifespan Biosciences Inc
Priority to AU2002239417A priority Critical patent/AU2002239417A1/en
Publication of WO2002044737A2 publication Critical patent/WO2002044737A2/fr
Priority to US10/206,395 priority patent/US20030157570A1/en
Publication of WO2002044737A3 publication Critical patent/WO2002044737A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Psychology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des applications diagnostiques, thérapeutiques et autres applications analogues fondés sur le récepteur anaphylatoxine C3a permettant de lutter contre la maladie d'Alzheimer et contre la maladie de Parkinson. Les compositions et les méthodes décrites dans cette invention peuvent comprendre un ou plusieurs des éléments suivants: peptide, protéine, anticorps, et composants d'acides nucléiques, qui peuvent être utiles, par exemple, comme agonistes, antagonistes, sondes, compositions de thérapie génique ou compositions antisens ainsi que de différentes autres manières.
PCT/US2001/045220 2000-11-29 2001-11-29 Compositions pour applications diagnostiques et therapeutiques et methodes associees au recepteur couple aux proteines g (gpcr) le recepteur anaphylatoxine c3a WO2002044737A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2002239417A AU2002239417A1 (en) 2000-11-29 2001-11-29 Diagnostic and therapeutic compositions and methods related to anaphylatoxin c3a receptor
US10/206,395 US20030157570A1 (en) 2001-10-17 2002-07-26 Diagnostic and therapeutic compositions and methods related to G protein-coupled receptor (GPCR) anaphylatoxin C3a receptor

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US25025100P 2000-11-29 2000-11-29
US60/250,251 2000-11-29
US25045200P 2000-11-30 2000-11-30
US60/250,452 2000-11-30
US33003601P 2001-10-17 2001-10-17
US60/330,036 2001-10-17

Publications (2)

Publication Number Publication Date
WO2002044737A2 WO2002044737A2 (fr) 2002-06-06
WO2002044737A3 true WO2002044737A3 (fr) 2003-05-15

Family

ID=27400298

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/045220 WO2002044737A2 (fr) 2000-11-29 2001-11-29 Compositions pour applications diagnostiques et therapeutiques et methodes associees au recepteur couple aux proteines g (gpcr) le recepteur anaphylatoxine c3a

Country Status (2)

Country Link
AU (1) AU2002239417A1 (fr)
WO (1) WO2002044737A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002044737A2 (fr) * 2000-11-29 2002-06-06 Lifespan Biosciences, Inc. Compositions pour applications diagnostiques et therapeutiques et methodes associees au recepteur couple aux proteines g (gpcr) le recepteur anaphylatoxine c3a
WO2004082566A2 (fr) * 2003-03-17 2004-09-30 Bayer Healthcare Ag Methodes diagnostiques et therapeutiques de maladies associees au recepteur 1 du composant de complement 3a (c3ar1)
WO2005101013A2 (fr) * 2004-04-15 2005-10-27 Reglia Ab Substances et procedes pour le criblage de modulateurs de la regeneration neuronale
EP2510949A4 (fr) 2009-12-11 2013-11-13 Astellas Pharma Inc Agent thérapeutique pour la fibromyalgie
GB201619637D0 (en) 2016-11-21 2017-01-04 Pekna Marcela And Pekny Milos And Stokowska Anna C3a receptor agonists

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999015490A1 (fr) * 1997-09-23 1999-04-01 Smithkline Beecham Corporation Ligands pour recepteurs de c3a
US5942405A (en) * 1996-06-17 1999-08-24 Smithkline Beecham Corporation Therapeutic and screening methods using C3a receptor and C3a
US5989592A (en) * 1996-10-03 1999-11-23 Coastside Bio Resources Inhibition of complement pathway by sea cucumber fractions
WO2002044737A2 (fr) * 2000-11-29 2002-06-06 Lifespan Biosciences, Inc. Compositions pour applications diagnostiques et therapeutiques et methodes associees au recepteur couple aux proteines g (gpcr) le recepteur anaphylatoxine c3a

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5942405A (en) * 1996-06-17 1999-08-24 Smithkline Beecham Corporation Therapeutic and screening methods using C3a receptor and C3a
US5989592A (en) * 1996-10-03 1999-11-23 Coastside Bio Resources Inhibition of complement pathway by sea cucumber fractions
WO1999015490A1 (fr) * 1997-09-23 1999-04-01 Smithkline Beecham Corporation Ligands pour recepteurs de c3a
WO2002044737A2 (fr) * 2000-11-29 2002-06-06 Lifespan Biosciences, Inc. Compositions pour applications diagnostiques et therapeutiques et methodes associees au recepteur couple aux proteines g (gpcr) le recepteur anaphylatoxine c3a

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KRETZSCHMAR T ET AL: "Synthetic peptides as antagonists of the anaphylatoxin C3a", EUROPEAN JOURNAL OF BIOCHEMISTRY, BERLIN, DE, vol. 210, no. 1, 15 November 1992 (1992-11-15), pages 185 - 191, XP002116090, ISSN: 0014-2956 *
ROGLIC A ET AL: "CDNA CLANING OF A NOVEL G PROTEIN-COUPLED RECEPTOR WITH A LARGE EXTRACELLULAR LOOP STRUCTURE", BIOCHIMICA ET BIOPHYSICA ACTA, AMSTERDAM, NL, vol. 1305, 1996, pages 39 - 43, XP000609693, ISSN: 0006-3002 *

Also Published As

Publication number Publication date
AU2002239417A1 (en) 2002-06-11
WO2002044737A2 (fr) 2002-06-06

Similar Documents

Publication Publication Date Title
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
WO2005014035A3 (fr) Utilisation de galactose oxydase pour la conjugaison chimique selective de molecules d'extraction a des proteines d'interet therapeutique
ATE269402T1 (de) Ikk-beta proteine, nukleinsäuren und verfahren
WO2003057837A3 (fr) Procedes d'utilisation d'anticorps anti-muc18
WO2002008285A3 (fr) Molecules il-17 et leurs utilisations
WO2000073469A3 (fr) Proteines kinases
MXPA03002413A (es) Moleculas tipo b7 y uso de las mismas.
WO2001070977A3 (fr) Molecules analogues au recepteur du facteur de croissance du fibroblaste, et leurs utilisations
WO2002014500A3 (fr) Genes humains et produits d'expression genique
WO2001066753A3 (fr) Nouveaux genes humains et leurs produits d'expression
WO2002000724A3 (fr) Molecules de recepteur de lymphopoietine de stroma thymique et utilisations de celles-ci
WO2001061007A3 (fr) Molecules du facteur 23 de croissance de fibroblastes et procedes d'utilisation correspondants
WO2001068859A3 (fr) Molecules du type recepteur de l'interleukine 17 et leur utilisation
WO2001055178A3 (fr) Compositions et methodes de traitement de cancer
WO2001068854A3 (fr) Molecules s'apparentant au facteur de croissance des fibroblastes et leurs utilisations
WO2001042474A3 (fr) Molecules de type interferon et utilisations
WO2002044737A3 (fr) Compositions pour applications diagnostiques et therapeutiques et methodes associees au recepteur couple aux proteines g (gpcr) le recepteur anaphylatoxine c3a
WO2001057219A3 (fr) Cytokines mammaliennes, leurs recepteurs, reactifs et procedes correspondants
WO2005019259A3 (fr) Variants de l'antagoniste du recepteur d'interleukine-1: compositions et utilisations correspondantes
EP2088197A3 (fr) Antigènes de Haemophilus influenzae et fragments d'ADN correspondants
WO1999066051A3 (fr) Kinases en rapport avec nek et avec bub1
WO2003076658A3 (fr) Gene de predisposition a la maladie de parkinson idiopathique a apparition tardive
PL374550A1 (en) Il-17 like molecules and uses thereof
MXPA03010728A (es) Moleculas de proteina-2 relacionadas con b7 y uso de las mismas.
WO2001074903A3 (fr) Molecules du type recepteur de cd20/ige et leurs applications

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP